Effects of Roflumilast on Exacerbations and Lung Function in COPD Patients with Bronchiectasis
Year: 2025
Type: article
Study design: Observational Study
Abstract: /FVC) ratio (p=0.015) compared to no roflumilast group. In multivariate analysis, roflumilast use was independently associated with a higher exacerbation risk (p=0.004, OR=14.643, 95% CI: 2.36-90.848). While roflumilast improved pulmonary function and symptoms in COPD patients with bronchiectasis, it was also linked to a higher risk of exacerbations. These findings suggest caution in its use for this population, and further randomized controlled trials are needed to assess its safety and efficacy.
Source: Chonnam Medical Journal
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4414682199